Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals

Arielle J Labiner; Anne Aronson; Aimee L Lucas

doi:10.1016/j.hoc.2022.06.004

Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals

Hematol Oncol Clin North Am. 2022 Oct;36(5):929-942. doi: 10.1016/j.hoc.2022.06.004.

Authors

Arielle J Labiner¹, Anne Aronson¹, Aimee L Lucas²

Affiliations

¹ Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
² Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: aimee.lucas@mssm.edu.

PMID: 36265991
DOI: 10.1016/j.hoc.2022.06.004

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality, largely due to late stage at diagnosis. Approximately 10% to 15% are hereditary, and detection of early stage PDAC or precursor lesions through pancreatic surveillance programs may improve outcomes. Current surveillance is annual, typically with endoscopic ultrasound and/or magnetic resonance imaging.

Keywords: Cancer screening; Consensus guidelines; Familial pancreatic cancer; High-risk; Pancreatic ductal adenocarcinoma; Pancreatic surveillance.

Publication types

Review

MeSH terms

Adenocarcinoma* / diagnostic imaging
Carcinoma, Pancreatic Ductal* / diagnostic imaging
Carcinoma, Pancreatic Ductal* / genetics
Early Detection of Cancer / methods
Humans
Pancreatic Neoplasms* / diagnostic imaging
Pancreatic Neoplasms* / genetics
Risk Factors